Stark Pharma Profile
Key Indicators
- Authorised Capital ₹ 5.00 Cr
- Paid Up Capital ₹ 4.52 Cr
- Company Age 10 Year, 1 Month
- Last Filing with ROC 31 Mar 2023
- Revenue Growth 175.49%
- Profit Growth 143.65%
- Ebitda -491.44%
- Net Worth 3.68%
- Total Assets -1.47%
About Stark Pharma
Stark Pharma Private Limited (SPPL) is a Private Limited Indian Non-Government Company incorporated in India on 26 December 2014 and has a history of Ten years and one month. Its registered office is in Hyderabad, Telangana, India.
The Corporate was formerly known as Stark Pharma Soft Tech Private Limited. The Company is engaged in the Business Outsourcing Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 5.00 Cr and a paid-up capital of Rs 4.52 Cr, as per Ministry of Corporate Affairs (MCA) records.
Teja Darapureddy, Parvataneni Rao, and Prathipati Kalyani serve as directors at the Company.
Company Details
-
Location
Hyderabad, Telangana, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
Social Media
Corporate Identity Details
-
CIN/LLPIN
U72900TG2014PTC097007
-
Company No.
097007
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
26 Dec 2014
-
Date of AGM
30 Sep 2023
-
Date of Balance Sheet
31 Mar 2023
-
Listing Status
Unlisted
-
ROC Code
Roc Hyderabad
Industry
Who are the key members and board of directors at Stark Pharma?
Board Members (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Teja Darapureddy
|
Director | 03-May-2024 | Current |
|
Parvataneni Rao
|
Director | 01-Dec-2018 | Current |
|
Prathipati Kalyani
|
Director | 17-Mar-2023 | Current |
Financial Performance of Stark Pharma.
Stark Pharma Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 175.49% increase. The company also saw a substantial improvement in profitability, with a 143.65% increase in profit. The company's net worth moved up by a moderate rise of 3.68%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Stark Pharma?
In 2022, Stark Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
-
Highlyfresh Farms LlpTeja Darapureddy is a mutual person
-
Clarius Pharmaceuticals Private Limited
Teja Darapureddy is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Stark Pharma?
Unlock and access historical data on people associated with Stark Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Stark Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Stark Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
